Results 1 - 20 of 44.
Health - Pharmacology - 15.02.2024
New therapeutic avenues to improve ovarian cancer treatment
By studying for the first time the effects of chemotherapy on certain cells in the tumor microenvironment , a team from the Institut Curie and Inserm, led by Dr. Fatima Mechta-Grigoriou, has taken a major step towards understanding the mechanisms of chemotherapy resistance in ovarian cancer patients.
Health - Pharmacology - 24.11.2023
Effective non-invasive ultrasound therapy in the treatment of heart valve diseases
Adobe stock Currently, the treatment of heart valve diseases relies on the replacement of the dysfunctional valve with an artificial prosthesis. However, this procedure cannot be offered to all patients due to its invasive nature.
Pharmacology - Life Sciences - 28.08.2023
A major step forward in the treatment of narcolepsy
Difficulty staying awake may seem trivial, but it's the main symptom of one of the most severe sleep disorders: narcolepsy. In Montpellier, the Centre de référence des narcolepsies et hypersomnies rares (Inserm/University/CHU de Montpellier) headed by Yves Dauvilliers is conducting cutting-edge research into this disease.
Health - Pharmacology - 27.07.2023
Remission from HIV-1 infection: discovery of broadly neutralizing antibodies that contribute to virus control
Antibody fragments of EPCT112 bNAb (blue) discovered at the Institut Pasteur by Hugo Mouquet's team, here forming a complex with the HIV-1 envelope protein (Env) (shown in yellow and orange Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption.
Health - Pharmacology - 11.07.2023
A global overview of antibiotic resistance determinants
To understand the main determinants behind worldwide antibiotic resistance dynamics, scientists from the Institut Pasteur, Inserm, Université de Versailles Saint-Quentin-en-Yvelines and Université Paris-Saclay developed a statistical model based on a large-scale spatial-temporal analysis. Using the ATLAS antimicrobial resistance surveillance database, the model revealed significant differences in trends and associated factors depending on bacterial species and resistance to certain antibiotics.
Health - Pharmacology - 23.05.2023
A marine worm, life saver
In 2020, in the midst of the COVID-19 crisis, we spoke with Franck Zal, a doctor in marine biology from Sorbonne University and founder of the company Hemarina. At the time, HEMO2life - their flagship product created from the hemoglobin of the marine worm, the arenicole - was envisaged to improve the oxygenation of patients suffering from acute respiratory distress syndrome.
Health - Pharmacology - 11.04.2023
A New Target to Regress Liver Fibrosis
Cirrhosis is the final stage of fibrosis associated with chronic liver diseases. It affects 200,000 to 500,000 individuals in France and is responsible for 170,000 deaths per year in Europe. Adobe Stock Chronic liver diseases are characterized by persistent inflammation that contributes to their progression to more severe stages.
Health - Pharmacology - 23.03.2023
Covid-19: infection-vaccination combination best protects against reinfection with SARS-CoV-2
Publication of the CIRI in the journal Science Translational Medicine on March 15, 2023. Press realease of the INSERM on March 17, 2023. A large proportion of the population has developed immunity to SARS-CoV-2 following infection and/or vaccination. In addition, some infected patients benefit from a so-called "hybrid" immunity when they have been vaccinated after their infectious episode.
Health - Pharmacology - 21.03.2023
COVID-19: Infection-Vaccination is the Most Protective Combination Against Reinfection
A large part of the population has developed immunity against SARS-CoV-2 following infection, vaccination - or both. In addition, some infected patients enjoy "hybrid” immunity when they are vaccinated following their infectious episode. Scientists from Inserm, CNRS, Université Claude-Bernard Lyon 1 and ENS de Lyon at the International Center for Research on Infectious Diseases (CIRI) seek to characterize the imprint left by SARS-CoV-2 exposure through vaccination or the combination of the two events on immune memory.
Health - Pharmacology - 14.03.2023
Pancreatic cancer: discovery of a molecular test allows for personalized treatment
Inserm researchers at the Marseille Cancer Research Center (CRCM - AMU/Inserm/CNRS/IPC) and clinicians at the Paoli-Calmettes Institute (IPC) have identified a molecular test for personalized treatment of pancreatic cancer. This new strategy, based on the prediction of the sensitivity of each patient to the different chemotherapy protocols currently available, opens the way to personalized treatments for pancreatic cancer.
Health - Pharmacology - 07.03.2023
A New Milestone in the Development of an Effective Allergic Asthma Vaccine
To combat allergic asthma, which affects millions of people worldwide, scientists from Inserm, CNRS and Université Toulouse III-Paul Sabatier at the Infinity laboratory , Institut Pasteur and French company NEOVACS are developing and testing a new vaccine. In their previous study, the teams had shown it to be effective in producing antibodies capable of neutralizing human immune proteins that play a key role in triggering allergic asthma, cytokines IL-4 and IL-13.
Health - Pharmacology - 20.02.2023
Obesity and overweight: nearly one French person in two is affected
Obesity is a global public health problem with an increasing incidence. According to the WHO, since 1975, the number of obesity cases has almost tripled worldwide . Obesity is associated with numerous comorbidities and high mortality. It is estimated that this complex chronic disease increases the risk of cardiovascular disease (first cause of death in the world), diabetes, musculoskeletal disorders, many forms of cancer (endometrial, breast, ovarian, prostate, liver, gallbladder, kidney and colon.
Health - Pharmacology - 17.02.2023
Better understand the transition from acute to chronic pain
Researchers from the University of Montpellier and Inserm at the Montpellier Neuroscience Institute have shown the preponderant role of the FLT3 receptor in chronic post-surgical pain. By inhibiting this receptor with therapeutic antibodies, the scientists could propose promising avenues for the prevention of chronic pain.
Health - Pharmacology - 17.01.2023
Immunotherapy: a new two-in-one weapon against resistant tumors
Pressing the gas pedal and lifting the brake at the same time is the innovative idea of Dr. Nicolas Manel, Inserm researcher and team leader at the Institut Curie (Immunity and Cancer Unit - Institut Curie, Inserm) to improve the response to immunotherapies. For several years, the researchers have identified a signaling pathway - STING - that is essential for accelerating the response to immunotherapies.
Pharmacology - Life Sciences - 28.11.2022
Development of a pentavalent vaccine against New World arenaviruses
Publication of the CIRI in the journal Nature Microbiology on January 5, 2023. Communication of the Institut Pasteur on January 6, 2023. A team from the Institut Pasteur, hosted at CIRI, has developed and successfully tested on a primate model a pentavalent vaccine against the five pathogenic arenaviruses circulating in South America.
Health - Pharmacology - 09.11.2022
Long COVID: A Dysregulated Immune Response Could Explain Symptoms Persistence
Several months after SARS-CoV-2 infection, some patients continue to have symptoms. This phenomenon, known as "post-COVID condition” or, more commonly, "long COVID”, remains poorly documented. In order to address this and improve patient care, research teams are trying to improve their understanding of the underlying biological and immunological mechanisms.
Pharmacology - Health - 04.10.2022
Chemotherapy: towards a simplified subcutaneous administration
The treatment of cancer is often based on intravenous chemotherapy, which is highly demanding and requires hospitalisation. One of the possibilities considered to alleviate this protocol is subcutaneous chemotherapy. Though much simpler to implement and more comfortable for the patient, it is impossible to practice as most of the active ingredients administered are irritant and vesicant - they stagnate in the subcutaneous tissue where they cause skin necrosis due to their high toxicity.
Health - Pharmacology - 28.06.2022
Highly Effective Memory B Cells Localized in the Lungs
How can we increase the efficacy of vaccines used to protect against viral respiratory diseases such as influenza and COVID-19? Scientists from Inserm, CNRS and Aix-Marseille Université at the Center of Immunology Marseille-Luminy are opening up new prospects in the field, with the triggering of memory B cells directly in the lungs looking to be a promising avenue.
Health - Pharmacology - 04.05.2022
Influenza: A New Avenue for Developing Innovative Treatments
Seasonal influenza is a major public health issue because it continues to remain associated with considerable mortality, particularly among people who are elderly, immunocompromised, or both. It also has a significant socioeconomic cost. With vaccination and current treatments still being of limited efficacy, research teams are trying to develop new therapeutic approaches.
Health - Pharmacology - 20.04.2022
Infertility: New Avenues to Understand the Harmful Effects of Chemotherapy
Infertility is a public health problem affecting millions of couples in France. Among the possible causes, chemotherapy has been singled out as having particularly harmful effects on the fertility of both women and men. In order to better prevent and restore fertility in cancer survivors, understanding the mechanisms behind these negative effects is a priority.